The therapeutic potential of antibodies in cancer immunotherapy can be affected by their capacity to modulate T cell states within the tumor microenvironment (TME). T cell exhaustion represents a hypofunctional state characterized by reduced effector function and increased inhibitory receptor expression that arises from persistent antigen exposure and a hostile microenvironment. As this state often undercuts the efficacy of T cell–based therapies, including bispecific antibodies and immune checkpoint inhibitors, there is growing interest in strategies to reverse or circumvent exhaustion. However, the biological mechanisms that drive T cells to become dysfunctional resulting in the accumulation of terminally exhausted or senescent T cells remain incompletely understood.
The up-regulated expression of co‐inhibitory receptors like PD-1, CTLA-4, LAG-3, TIM‐3, and TIGIT, can impair T cell function via distinct molecular pathways, contributing to immune evasion and cancer progression. A recent review describes the therapeutic promise of immune checkpoint inhibitors (ICIs) in reversing T cell exhaustion and the complex molecular processes and functional works of these important co‐inhibitory receptors in tumourigenesis.
The integration of bispecific antibodies provides dual-targeting capabilities that may enhance specificity and synergy when combined with immune checkpoint blockade. This dual approach is poised to redefine immune engagement by simultaneously disrupting exhaustion pathways and directing effector T cells toward tumor-associated antigens.
A paper published this week by a team at the University of Pennsylvania highlighted a novel bispecific antibody design to overcome T cell exhaustion. They developed NanoBiTEs, drug-loaded bispecific T cell nanoengagers, which combine tumor and T cell targeting via anti-CD19 and anti-CD3 antibodies with localized release of the adenosine A2A receptor antagonist PBF-509. In preclinical models, NanoBiTEs outperformed conventional bispecific T cell engagers such as blinatumomab by suppressing adenosine-mediated immunosuppression and thus reducing T cell exhaustion. Adenosine-A2AR signaling activation also contributes to the upregulation of immune inhibitory receptors such as PD-1, CTLA-4, and LAG-3, which affect T cell exhaustion as mentioned before. The result was a marked increase in tumor cell killing and improved tumor control in vivo, positioning NanoBiTEs as a next-generation modality that addresses both cellular targeting and immunometabolic reprogramming.
A recent paper takes a perspective on immunotherapy for lung cancer patients. Elevated expression of multiple inhibitory receptors has been well-documented in lung cancer patients, signifying a state of T cell exhaustion. Further complicating the treatment landscape, resistance to PD-1 inhibitors in lung cancer has been correlated with upregulation of other immune checkpoints such as TIM-3 and LAG-3 in mouse models. Emerging strategies include modulation of exhaustion pathways through antibody-based interventions, immune checkpoint inhibitors, and adoptive T cell transfer. In NSCLC, combining antibodies that target co-inhibitory receptors with those that promote T cell activation could offer synergistic benefit, especially when informed by molecular profiling of T cell exhaustion states.
While T cell exhaustion is clearly a challenge, the definition of the term itself is wide-ranging. In a Viewpoint article, 18 experts in the field tell us what exhaustion means to them, ranging from complete lack of effector function to altered functionality to prevent immunopathology, with potential differences between cancer and chronic infection. They emphasize the distinction between terminally differentiated exhausted T cells that are TCF1– and the self-renewing TCF1+ population from which they derive. These TCF1+ cells are considered by some to have stem cell-like properties akin to memory T cell populations, but the developmental relationships are still unclear. Recent studies have also hinted at an important role for the transcriptional regulator TOX in driving the epigenetic enforcement of exhaustion, but key questions remain about the potential to reverse the epigenetic program of exhaustion and how this might affect the persistence of T cell populations.
Further attempts to define T cell exhaustion include a recent study by a group at the University of Pittsburgh. We know the mechanisms by which oxidative stress drives T cell dysfunction, but little is known about the role of reactive oxygen species (ROS) impacting genomic stability in T cells. Here, they bring to light the role of telomere health in T cell function, especially under stressful physiologic conditions that induce exhaustion. The accumulation of mitochondrial ROS can induce telomere damage leading to T cell hypofunctionality. Tpex (progenitor exhausted) may harbor inherent dysfunction due to local exposures, which may drive generation of terminally dysfunctional T cells in the TME.
As we continue to research T cell exhaustion, these advances will drive a deeper understanding of T-cell biology and open new directions for next-generation cancer immunotherapies.
Biointron’s Q3 2025 antibody industry report aims to explore the events and tren……
Over the past few months, the biotech landscape saw venture funding of antibody ……
As viral threats continue to emerge and evolve, a new generation of antibody for……
In recent years, the development of nanoparticles has expanded into a large rang……
You can also contact us on the Scientist and Science Exchange marketplaces.
